# Comparing Individualized vs. Weight Based Protocols to Treat Vaso-Occlusive Episodes in Sickle Cell Disease

> **NCT03933397** · PHASE3 · TERMINATED · sponsor: **Duke University** · enrollment: 328 (actual)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **OTHER:** Patient-Specific Protocol
- **OTHER:** Weight-based Protocol
- **DRUG:** Morphine
- **DRUG:** Hydromorphone

## Key facts

- **NCT ID:** NCT03933397
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-08-13
- **Primary completion:** 2022-05-13
- **Final completion:** 2022-05-20
- **Target enrollment:** 328 (ACTUAL)
- **Why stopped:** Due to COVID enrollment numbers needed to meet the primary endpoint will not be met.
- **Last updated:** 2023-07-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03933397

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03933397, "Comparing Individualized vs. Weight Based Protocols to Treat Vaso-Occlusive Episodes in Sickle Cell Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03933397. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*